<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394132</url>
  </required_header>
  <id_info>
    <org_study_id>ANZMTG 02.12</org_study_id>
    <nct_id>NCT02394132</nct_id>
  </id_info>
  <brief_title>Radiotherapy or Imiquimod in Complex Lentigo Maligna</brief_title>
  <acronym>RADICAL</acronym>
  <official_title>A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australia and New Zealand Melanoma Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Melanoma Institute Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australia and New Zealand Melanoma Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of using either radiotherapy
      (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is
      refused, or fails.

      Surgery is the standard treatment for people diagnosed with LM. However for some people, it
      may not be possible due to the location of their LM lesion(s).

      Currently, the Australian and New Zealand Melanoma Treatment Guidelines recommend
      radiotherapy for the treatment of LM however there is no clinical trial evidence for this and
      a trial is needed to prove which treatment is safer and more effective. Some clinicians may
      also recommend the use of a cream called Imiquimod. It is approved and widely used in
      Australia to treat solar keratosis, superficial basal cell carcinoma, external genital warts,
      and perianal warts. Although not currently licensed for treatment use in LM, there is some
      evidence to suggest that it is both safe and effective in treating LM.

      This trial will scientifically evaluate and compare these two treatments in a controlled
      clinical setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing LM treatment failure (as determined by systematic biopsy) 6 months following completion of treatment.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LM treatment failure at 12 months and 24 months after the completion of treatment.</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using Skindex questionnaire</measure>
    <time_frame>0-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome 24 months after treatment or at treatment failure</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluated using photographs taken of LM lesion(s) during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive melanoma within treatment fields; a sub-study to evaluate the utility of reflectance confocal microscopy (RCM) compared with standard biopsy in diagnosing recurrence</measure>
    <time_frame>0-24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Lentigo Maligna</condition>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical imiquimod 5% cream
application to treatment area for 5 days/week for a total of 12 weeks
dispensed at baseline visit along with patient diary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy
treatment regimen determined by treating radiation oncologist and as per standard practice at local institution
treatment to commence within 8 weeks of randomisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <arm_group_label>Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 years or older.

          2. A biopsy-proven LM. This includes previous treatment failures (not with imiquimod or
             RT) of LM that are diagnosed as biopsy-proven LM.

          3. LM that is in a location amenable to treatment with imiquimod and radiotherapy.

          4. Willing and able to comply with study requirements.

          5. Written informed consent.

        Exclusion Criteria:

          1. Invasive melanoma.

          2. Medical or psychiatric condition that compromises the ability of the patient to
             complete protocol treatment or follow-up assessments.

          3. Patients who are pregnant or lactating. Women of child bearing potential must have a
             confirmed negative urine pregnancy test at study entry.

          4. Life expectancy of less than 2 years.

          5. Radiotherapy sensitivity syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Guitera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melanoma Institute Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANZMTG Coordinator</last_name>
    <phone>612 9911 7352</phone>
    <email>radical@melanoma.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gallagher</last_name>
      <phone>02 4014 3949</phone>
      <email>sarah.gallagher@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Chris Wratten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gonzalez</last_name>
      <phone>612 9911 7200</phone>
      <email>maria.gonzalez@melanoma.org.au</email>
    </contact>
    <investigator>
      <last_name>Pascale Guitera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaya St George</last_name>
      <email>gstgeorge@scfa.edu.au</email>
    </contact>
    <investigator>
      <last_name>Pablo Fernandez Penas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Ali</last_name>
      <email>marina.ali@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Pablo Fernandez Penas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital, Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Bryce</last_name>
      <email>louise.bryce@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Gerald Fogarty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Primiero</last_name>
      <phone>07 3443 7496</phone>
      <email>c.bover@uq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Matt Foote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Mellberg</last_name>
      <email>Anne.Mellberg@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Shireen Sidhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Brack</last_name>
      <email>j.brack@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Victoria Mar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0740</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gill Rolfe</last_name>
      <phone>+64 9 4868 920</phone>
      <phone_ext>7125</phone_ext>
      <email>Gill.Rolfe@waitematadhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Richard Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lentigo maligna</keyword>
  <keyword>Imiquimod</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
    <mesh_term>Hutchinson's Melanotic Freckle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

